PM418. Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies

Documenti analoghi

• Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
  di: Nasrallah, Henry A., et al.
  Pubblicazione: (2014)
• Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
  di: Meyer, Jonathan M., et al.
  Pubblicazione: (2015)
• A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
  di: Tandon, Rajiv, et al.
  Pubblicazione: (2016)
• PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone
  di: Newcomer, John W., et al.
  Pubblicazione: (2016)
• Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
  di: Goldman, Robert, et al.
  Pubblicazione: (2017)